Galecto Overview
- Year Founded
-
2011

- Status
-
Public
- Employees
-
2

- Stock Symbol
-
GLTO

- Investments
-
2
- Share Price
-
$4.78
- (As of Friday Closing)
Galecto General Information
Description
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Contact Information
Website
www.galecto.comCorporate Office
- Ole Maaloes Vej 3
- 2200 Copenhagen
- Denmark
Corporate Office
- Ole Maaloes Vej 3
- 2200 Copenhagen
- Denmark
Galecto Stock Performance
As of 14-Feb-2025, Galecto’s stock price is $4.78. Its current market cap is $6.3M with 1.32M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$4.78 | $4.58 | $4.24 - $23.50 | $6.3M | 1.32M | 19K | -$19.11 |
Galecto Financials Summary
As of 30-Sep-2024, Galecto has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | (7,619) | (24,193) | (38,808) | (24,662) |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (21,616) | (39,208) | (61,856) | (51,467) |
Net Income | (21,173) | (38,349) | (61,624) | (51,752) |
Total Assets | 23,376 | 38,227 | 73,188 | 122,215 |
Total Debt | 32 | 249 | 804 | 847 |
Galecto Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Galecto Comparisons
Industry
Financing
Details
Galecto Competitors (53)
One of Galecto’s 53 competitors is Morphic Therapeutic, a Formerly VC-backed company based in Waltham, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Morphic Therapeutic | Formerly VC-backed | Waltham, MA | ||||
Pliant Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
Syntara | Formerly VC-backed | Frenchs Forest, Australia | ||||
Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
Marinus Pharmaceuticals | Formerly VC-backed | Radnor, PA |
Galecto Patents
Galecto Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20240059728-A1 | Novel galactoside inhibitor of galectins | Pending | 10-Feb-2021 | ||
CA-3203618-A1 | Novel galactoside inhibitor of galectins | Pending | 28-Dec-2020 | ||
EP-4267568-A1 | Novel galactoside inhibitor of galectins | Pending | 28-Dec-2020 | ||
US-20240309038-A1 | Novel galactoside inhibitor of galectins | Pending | 28-Dec-2020 | ||
CA-3205493-A1 | Novel galactoside inhibitor of galectins | Pending | 22-Dec-2020 | C07D417/14 |
Galecto Signals
Galecto Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Galecto Investments & Acquisitions (2)
Galecto’s most recent deal was a Corporate Asset Purchase with Bridge Medicines (Global Rights to BRM-1420). The deal was made on 07-Oct-2024.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Bridge Medicines (Global Rights to BRM-1420) | 07-Oct-2024 | Corporate Asset Purchase | Buildings and Property | ||
PharmAkea Therapeutics | 31-Dec-2019 | Merger/Acquisition | Biotechnology |
Galecto ESG
Risk Overview
Risk Rating
Updated April, 20, 2023
33.01 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,048
Rank
Percentile

Pharmaceuticals
Industry
of 914
Rank
Percentile

Pharmaceuticals
Subindustry
of 451
Rank
Percentile

Galecto FAQs
-
When was Galecto founded?
Galecto was founded in 2011.
-
Where is Galecto headquartered?
Galecto is headquartered in Copenhagen, Denmark.
-
What is the size of Galecto?
Galecto has 2 total employees.
-
What industry is Galecto in?
Galecto’s primary industry is Drug Discovery.
-
Is Galecto a private or public company?
Galecto is a Public company.
-
What is Galecto’s stock symbol?
The ticker symbol for Galecto is GLTO.
-
What is the current stock price of Galecto?
As of 14-Feb-2025 the stock price of Galecto is $4.78.
-
What is the current market cap of Galecto?
The current market capitalization of Galecto is $6.3M.
-
Who are Galecto’s competitors?
Morphic Therapeutic, Pliant Therapeutics, Syntara, Dicerna Pharmaceuticals, and Marinus Pharmaceuticals are some of the 53 competitors of Galecto.
-
What is Galecto’s annual earnings per share (EPS)?
Galecto’s EPS for 12 months was -$19.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »